Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Sisram Medical Ltd. ( (HK:1696) ) is now available.
Sisram Medical has announced the completion of a reorganisation at the controlling shareholder level involving internal transfers of its shares among Fosun Pharma’s indirect wholly owned subsidiaries. Ample Up and Chindex have transferred their entire combined 71.42% stake in Sisram to FPI, another Fosun Pharma subsidiary, leaving Fosun Pharma’s overall indirect equity interest in the company unchanged and signalling no immediate shift in control or external ownership structure.
Following the completion of the transaction, FPI now directly holds 334,504,800 Sisram shares, consolidating Fosun Pharma’s controlling stake in the company under a single holding entity. The move streamlines the group’s ownership structure over Sisram, which may improve internal governance and capital management, while providing continuity and stability for minority shareholders since ultimate control remains with Fosun Pharma.
More about Sisram Medical Ltd.
Sisram Medical Ltd., incorporated in Israel and listed in Hong Kong, operates in the medical technology sector. The company is controlled indirectly by Shanghai Fosun Pharmaceutical (Fosun Pharma) through several subsidiaries, reflecting its integration into a larger healthcare and pharmaceutical conglomerate with a global investment footprint.
Average Trading Volume: 407,497
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.48B
For an in-depth examination of 1696 stock, go to TipRanks’ Overview page.